A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/ oxaliplatin (FOLFOX4) regimen

E. Cecchin; M. D'Andrea; S. Lonardi; C. Zanusso; N. Pella; D. Errante; E. De Mattia; J. Polesel; F. Innocenti; G. Toffoli

doi:10.1038/tpj.2012.31

A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/ oxaliplatin (FOLFOX4) regimen

E. Cecchin, M. D'Andrea, S. Lonardi, C. Zanusso, N. Pella, D. Errante, E. De Mattia, J. Polesel, F. Innocenti, G. Toffoli

Research output: Contribution to journal › Article › peer-review

Abstract

The discovery of pharmacogenomic markers in colorectal cancer (CRC) could be setting-specific. FOLFOX4 is employed in the adjuvant and metastatic setting in CRC. This prospective study is aimed to validate in the adjuvant setting the pharmacogenomic markers of toxicity reported in the metastatic setting (that is, GSTP1-rs947894, and -rs1138272; GSTM1-null genotype; AGXT-rs4426527, -rs34116584 and del-74 bp), and to discover additional markers. CRC patients (n=144) treated with adjuvant FOLFOX4 were genotyped for 57 polymorphisms in 29 genes. Grade ≥2 neurotoxicity was associated (false discovery rate-adjusted q-value

Original language	English
Pages (from-to)	403-409
Number of pages	7
Journal	Pharmacogenomics Journal
Volume	13
Issue number	5
DOIs	https://doi.org/10.1038/tpj.2012.31
Publication status	Published - Oct 2013

Keywords

colorectal cancer
FOLFOX4
neurotoxicity
pharmacogenomics

ASJC Scopus subject areas

Pharmacology
Molecular Medicine
Genetics

Access to Document

10.1038/tpj.2012.31

Cite this

Cecchin, E., D'Andrea, M., Lonardi, S., Zanusso, C., Pella, N., Errante, D., De Mattia, E., Polesel, J., Innocenti, F., & Toffoli, G. (2013). A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/ oxaliplatin (FOLFOX4) regimen. Pharmacogenomics Journal, 13(5), 403-409. https://doi.org/10.1038/tpj.2012.31

Cecchin, E, D'Andrea, M, Lonardi, S, Zanusso, C, Pella, N, Errante, D, De Mattia, E , Polesel, J, Innocenti, F & Toffoli, G 2013, 'A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/ oxaliplatin (FOLFOX4) regimen', Pharmacogenomics Journal, vol. 13, no. 5, pp. 403-409. https://doi.org/10.1038/tpj.2012.31

@article{b44c63f2e80543f89f58c93ee5d8ada2,

title = "A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/ oxaliplatin (FOLFOX4) regimen",

abstract = "The discovery of pharmacogenomic markers in colorectal cancer (CRC) could be setting-specific. FOLFOX4 is employed in the adjuvant and metastatic setting in CRC. This prospective study is aimed to validate in the adjuvant setting the pharmacogenomic markers of toxicity reported in the metastatic setting (that is, GSTP1-rs947894, and -rs1138272; GSTM1-null genotype; AGXT-rs4426527, -rs34116584 and del-74 bp), and to discover additional markers. CRC patients (n=144) treated with adjuvant FOLFOX4 were genotyped for 57 polymorphisms in 29 genes. Grade ≥2 neurotoxicity was associated (false discovery rate-adjusted q-value ",

keywords = "colorectal cancer, FOLFOX4, neurotoxicity, pharmacogenomics",

author = "E. Cecchin and M. D'Andrea and S. Lonardi and C. Zanusso and N. Pella and D. Errante and {De Mattia}, E. and J. Polesel and F. Innocenti and G. Toffoli",

year = "2013",

month = oct,

doi = "10.1038/tpj.2012.31",

language = "English",

volume = "13",

pages = "403--409",

journal = "Pharmacogenomics Journal",

issn = "1470-269X",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/ oxaliplatin (FOLFOX4) regimen

AU - Cecchin, E.

AU - D'Andrea, M.

AU - Lonardi, S.

AU - Zanusso, C.

AU - Pella, N.

AU - Errante, D.

AU - De Mattia, E.

AU - Polesel, J.

AU - Innocenti, F.

AU - Toffoli, G.

PY - 2013/10

Y1 - 2013/10

N2 - The discovery of pharmacogenomic markers in colorectal cancer (CRC) could be setting-specific. FOLFOX4 is employed in the adjuvant and metastatic setting in CRC. This prospective study is aimed to validate in the adjuvant setting the pharmacogenomic markers of toxicity reported in the metastatic setting (that is, GSTP1-rs947894, and -rs1138272; GSTM1-null genotype; AGXT-rs4426527, -rs34116584 and del-74 bp), and to discover additional markers. CRC patients (n=144) treated with adjuvant FOLFOX4 were genotyped for 57 polymorphisms in 29 genes. Grade ≥2 neurotoxicity was associated (false discovery rate-adjusted q-value

AB - The discovery of pharmacogenomic markers in colorectal cancer (CRC) could be setting-specific. FOLFOX4 is employed in the adjuvant and metastatic setting in CRC. This prospective study is aimed to validate in the adjuvant setting the pharmacogenomic markers of toxicity reported in the metastatic setting (that is, GSTP1-rs947894, and -rs1138272; GSTM1-null genotype; AGXT-rs4426527, -rs34116584 and del-74 bp), and to discover additional markers. CRC patients (n=144) treated with adjuvant FOLFOX4 were genotyped for 57 polymorphisms in 29 genes. Grade ≥2 neurotoxicity was associated (false discovery rate-adjusted q-value

KW - colorectal cancer

KW - FOLFOX4

KW - neurotoxicity

KW - pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=84884587739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884587739&partnerID=8YFLogxK

U2 - 10.1038/tpj.2012.31

DO - 10.1038/tpj.2012.31

M3 - Article

C2 - 22868256

AN - SCOPUS:84884587739

SN - 1470-269X

VL - 13

SP - 403

EP - 409

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

IS - 5

ER -

A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/ oxaliplatin (FOLFOX4) regimen

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this